Ohta Yasuyuki, Yamashita Toru, Nomura Emi, Hishikawa Nozomi, Ikegami Ken, Osakada Yosuke, Matsumoto Namiko, Kawahara Yuko, Yunoki Taijun, Takahashi Yoshiaki, Takamiya Motonori, Tadokoro Koh, Sasaki Ryo, Nakano Yumiko, Tsunoda Keiichiro, Sato Kota, Omote Yoshio, Takemoto Mami, Abe Koji
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
J Neurol Sci. 2020 Aug 15;415:116906. doi: 10.1016/j.jns.2020.116906. Epub 2020 May 15.
The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS). Our objective was to evaluate the therapeutic effects of edaravone for oxidative stress and anti-oxidative activity in ALS patients.
Twenty-two ALS patients with a disease duration of 2 years, treated by edaravone, and 25 control participants were evaluated according to their clinical scores, including ALS functional rating scale-revised (ALSFRS-R), and serum and cerebrospinal fluid (CSF) markers of oxidative stress dROM and anti-oxidative activity OXY.
Serum and CSF markers of anti-oxidative activity OXY were significantly decreased in ALS patients at pre-treatment compared with controls (p < .01), which was improved in the course of edaravone treatment. Both serum and CSF OXY were significantly correlated with ALS clinical scores including ALSFRS-R (*p < .05, **p < .01, ***p < .001). Furthermore, serum OXY at pre-treatment was significantly correlated with a change in the ALSFRS-R score in the sixth cycle of edaravone treatment (*p < .05).
The present study suggests significant correlations between anti-oxidative activity and ALS clinical severity, and the therapeutic efficacy of edaravone for decreased anti-oxidative activity in ALS.
自由基清除剂依达拉奉是一种已被证实对肌萎缩侧索硬化症（ALS）患者具有神经保护作用的药物。我们的目的是评估依达拉奉对ALS患者氧化应激和抗氧化活性的治疗效果。
对22例病程2年且接受依达拉奉治疗的ALS患者以及25名对照参与者，根据其临床评分进行评估，包括修订的ALS功能评定量表（ALSFRS-R），以及氧化应激指标dROM和抗氧化活性指标OXY的血清和脑脊液（CSF）标志物。
与对照组相比，ALS患者治疗前抗氧化活性指标OXY的血清和脑脊液标志物显著降低（p <.01），在依达拉奉治疗过程中有所改善。血清和脑脊液中的OXY均与包括ALSFRS-R在内的ALS临床评分显著相关（*p <.05，**p <.01，***p <.001）。此外，治疗前血清OXY与依达拉奉治疗第六周期时ALSFRS-R评分的变化显著相关（*p <.05）。
本研究表明抗氧化活性与ALS临床严重程度之间存在显著相关性，以及依达拉奉对ALS患者抗氧化活性降低具有治疗效果。
